Skip to main content
. 2020 Jun 25;23(1):122–133. doi: 10.1093/neuonc/noaa145

Table 2.

Adverse events of any grade with a frequency >10%

AEs, n (%) 320 mg q.d. N = 20 480 mg q.d. N = 7 480 mg q.d., Fasted N = 17 All N = 44
All Grades Grade ≥3 All Grades Grade ≥3 All Grades Grade ≥3 All Grades Grade ≥3
Any AEs 16 (80.0) 6 (30.0) 7 (100.0) 5 (71.4) 15 (88.2) 10 (58.8) 38 (86.4) 21 (47.7)
Rash 6 (30.0) 0 2 (28.6) 0 6 (35.3) 1 (5.9) 14 (31.8) 1 (2.3)
Neutropenia 4 (20.0) 2 (100) 2 (71.4) 0 4 (20.0) 2 (11.8) 10 (22.7) 4 (9.1)
Leukopenia 2 (10.0) 1 (5.0) 3 (42.9) 0 3 (17.6) 2 (11.8) 8 (18.2) 3 (6.8)
Lymphopenia 2 (10.0) 0 3 (42.9) 2 (28.6) 2 (11.8) 1 (5.9) 7 (15.9) 3 (6.8)
Thrombocytopenia 1 (5.0) 0 3 (42.9) 0 1 (5.9) 0 5 (11.4) 0
Erythema multiforme 2 (10.0) 1 (5.0) 3 (42.9) 2 (28.6) 0 0 5 (11.4) 3 (6.8)
Constipation 1 (5.0) 0 0 0 4 (23.5) 0 5 (11.4) 0
Drug eruption 2 (10.0) 1 (5.0) 1 (14.3) 1 (14.3) 1 (5.9) 0 4 (9.1) 2 (4.5)
Blood bilirubin increased 4 (20.0) 1 (5.0) 0 0 0 0 4 (9.1) 1 (2.3)
Nausea 1 (5.0) 0 1 (14.3) 0 2 (11.8) 1 (5.9) 4 (9.1) 1 (2.3)
Stomatitis 2 (10.0) 0 1 (14.3) 0 1 (5.9) 0 4 (9.1) 0
Anemia 1 (5.0) 0 1 (14.3) 0 2 (11.8) 0 4 (9.1) 0
Vomiting 1 (5.0) 0 0 0 3 (17.6) 0 4 (9.1) 0
Aspartate aminotransferase  increased 2 (10.0) 1 (5.0) 0 0 1 (5.9) 1 (5.9) 3 (6.8) 2 (4.5)
Hypertriglyceridemia 0 0 0 0 3 (17.6) 2 (11.8) 3 (6.8) 2 (4.5)
Dyslipidemia 1 (5.0) 0 1 (14.3) 0 1 (5.9) 1 (5.9) 3 (6.8) 1 (2.3)
Seizure 1 (5.0) 0 0 0 2 (11.8) 1 (5.9) 3 (6.8) 1 (2.3)
Rash maculopapular 1 (5.0) 0 0 0 2 (11.8) 1 (5.9) 3 (6.8) 1 (2.3)
Urinary tract infection 0 0 2 (28.6) 0 1 (5.9) 1 (5.9) 3 (6.8) 1 (2.3)
Headache 2 (10.0) 0 1 (14.3) 0 0 0 3 (6.8) 0